Previous 10 | Next 10 |
Namodenoson is being evaluated in a pivotal Phase III study Namodenoson is approved for compassionate use in the treatment of liver cancer in Israel and Romania Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of pro...
Data show significant anti-cancer effect in pancreatic carcinoma as a monotherapy and an additive effect when combined with gemcitabine, the standard-of-care chemotherapy for pancreatic cancer Namodenoson’s excellent safety profile and its ability to directly inhibit the growth...
Can-Fite BioPharma ( NYSE: CANF ) has entered agreements for the purchase and sale of 1M ADSs at a purchase price of $5.50 per ADS, in a registered direct offering. In a concurrent private placement, the company has also agreed to issue and sell 363,637 of its ADS. The off...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases (“Can-Fite” or the “Company”), today announced that it has entered into def...
Can-Fite BioPharma ( NYSE: CANF ) said it submitted a market registration plan to the European Medicines Agency (EMA) for Piclidenoson to treat moderate to severe psoriasis. The company added that a submission to the U.S. Food and Drug Administration (FDA) will follow. Re...
As an oral treatment with an excellent safety and efficacy profile, Piclidenoson has potential for strong market position in $26 B psoriasis treatment market Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary sma...
Can-Fite BioPharma ( NYSE: CANF ) said it will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing 30 ordinary shares to a new ratio of one ADS representing 300 ordinary shares. The ratio change will be effective on January 9, 2023. ...
Israel-based Can-Fite BioPharma ( NYSE: CANF ) added ~13% pre-market Wednesday after the company shared its latest findings on its liver cancer therapy Namodenoson ahead of two investor conferences early next year. An experimental oral therapy, Namodenoson is targeted at hepatocel...
Results to be shared at Biotech Showcase during JP Morgan conference week in San Francisco and at BI0-CEO in New York An advanced CPB liver cancer patient remains clear of cancer 6 years following treatment with Namodenoson While CPB patients are typically excluded from li...
(NewsDirect) Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...